title: Novel microtubule-targeting agents - the epothilones.
abstract: Epothilones are a new class of antimicrotubule agents currently in clinical trials. Their chemical structures are distinct from taxanes and are more amenable to synthetic modification. Six epothilones have been studied in preclinical and clinical trials: patupilone (epothilone B), ixabepilone (BMS247550), BMS 310705, sagopilone (ZK-EPO), KOS-862 (epothilone D), and KOS-1584. In vitro data have shown increased potency in taxane-sensitive and taxane-resistant cancer cell lines. This enhanced cytotoxic effect has been attributed to epothilone being a poor substrate for p-glycoprotein drug resistance protein and having high affinity to the various beta tubulin isoforms. Phase I clinical data have shown different dose-limiting toxicities for each of the epothilones. These effects are drug specific, dose specific, and schedule of administration specific. While diarrhea and myelosuppression are the dose-limiting toxicities for patupilone and BMS 310705, respectively, neurologic toxicity, as seen with taxanes, is the dose-limiting toxicity of ixabepilone, sagopilone, and KOS-862. In an effort to decrease neurologic toxicity, investigators have modified dosing schedules with limited success. Ixabepilone has the most mature clinical results with published phase II and III data, and regulatory approval for clinical use in the treatment of breast cancer. Ixabepilone has also been combined with other anticancer agents and has regulatory approval in combination with capecitabine for heavily treated breast cancer.
authors.affiliation: Monter Cancer Center, North Shore - LIJ Health Systems, Lake Success, New York, USA.
authors.forename: Kit L
authors.initials: KL
authors.lastname: Cheng
authors.forename: Thomas
authors.initials: T
authors.lastname: Bradley
authors.forename: Daniel R
authors.initials: DR
authors.lastname: Budman
references.citation: Clin Cancer Res. 2005 Sep 1;11(17):6233-9
references.pmid: 16144926
references.citation: Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2904-9
references.pmid: 10688884
references.citation: Cancer Res. 2005 Oct 1;65(19):9021-8
references.pmid: 16204076
references.citation: Lancet Oncol. 2004 Mar;5(3):158-64
references.pmid: 15003198
references.citation: Curr Cancer Drug Targets. 2007 Dec;7(8):713-29
references.pmid: 18220532
references.citation: J Clin Oncol. 1999 Jun;17(6):1786-93
references.pmid: 10561216
references.citation: Cancer. 2007 Aug 1;110(3):556-63
references.pmid: 17577218
references.citation: Eur J Cancer. 2008 Mar;44(5):674-82
references.pmid: 18308561
references.citation: Cancer Res. 2002 Apr 1;62(7):1935-8
references.pmid: 11929805
references.citation: Clin Cancer Res. 2007 Dec 15;13(24):7480-6
references.pmid: 18094432
references.citation: Ann Oncol. 2007 Jul;18 Suppl 5:v9-15
references.pmid: 17656562
references.citation: Science. 2004 Aug 6;305(5685):866-9
references.pmid: 15297674
references.citation: Angew Chem Int Ed Engl. 2006 Dec 4;45(47):7942-8
references.pmid: 17006870
references.citation: Cancer Res. 2008 Jul 1;68(13):5380-9
references.pmid: 18593940
references.citation: J Clin Oncol. 2007 Aug 10;25(23):3407-14
references.pmid: 17606974
references.citation: Clin Cancer Res. 2005 Sep 1;11(17):6359-69
references.pmid: 16144941
references.citation: Cancer Chemother Pharmacol. 2008 Dec;63(1):157-66
references.pmid: 18347795
references.citation: Mol Cancer Ther. 2006 Sep;5(9):2348-57
references.pmid: 16985069
references.citation: Clin Cancer Res. 2007 Jul 15;13(14):4178-84
references.pmid: 17634546
references.citation: Oncology. 2006;71(3-4):292-6
references.pmid: 17657173
references.citation: J Clin Oncol. 2005 Mar 1;23(7):1439-46
references.pmid: 15735119
references.citation: Ann Oncol. 2004 Jun;15(6):928-32
references.pmid: 15151950
references.citation: J Clin Oncol. 2005 Dec 1;23(34):8724-9
references.pmid: 16314632
references.citation: Cancer. 2007 Aug 15;110(4):759-63
references.pmid: 17594721
references.citation: J Clin Oncol. 2007 Aug 10;25(23):3421-7
references.pmid: 17606971
references.citation: J Clin Oncol. 2005 May 1;23(13):3069-73
references.pmid: 15860865
references.citation: J Clin Oncol. 2007 Aug 10;25(23):3448-55
references.pmid: 17606973
references.citation: Invest New Drugs. 2007 Dec;25(6):565-70
references.pmid: 17618407
references.citation: Clin Cancer Res. 2008 Mar 15;14(6):1618-24
references.pmid: 18347162
references.citation: J Biol Chem. 1997 Jan 24;272(4):2534-41
references.pmid: 8999970
references.citation: Curr Pharm Des. 2005;11(13):1595-613
references.pmid: 15892665
references.citation: Cancer Sci. 2006 Sep;97(9):813-20
references.pmid: 16805818
references.citation: Clin Cancer Res. 2004 Feb 15;10(4):1289-98
references.pmid: 14977827
references.citation: J Biol Chem. 2005 Apr 1;280(13):12902-7
references.pmid: 15695826
references.citation: Cancer. 2013 May 1;119(9):1683-9
references.pmid: 23310949
references.citation: J Clin Oncol. 2007 Aug 10;25(23):3415-20
references.pmid: 17606972
references.citation: Cancer Res. 2008 Jul 1;68(13):5301-8
references.pmid: 18593931
references.citation: Mol Cancer Ther. 2005 Dec;4(12):2001-7
references.pmid: 16373715
references.citation: J Clin Oncol. 2003 May 1;21(9):1866-73
references.pmid: 12721265
references.citation: J Clin Oncol. 2005 Apr 20;23(12):2726-34
references.pmid: 15837987
references.citation: Clin Cancer Res. 2007 May 15;13(10):2849-54
references.pmid: 17504982
references.citation: Clin Cancer Res. 2008 May 1;14(9):2701-9
references.pmid: 18451235
references.citation: J Antibiot (Tokyo). 1996 Jun;49(6):560-3
references.pmid: 8698639
references.citation: Cancer Invest. 2005;23(5):479-80
references.pmid: 16193646
references.citation: Curr Drug Targets. 2000 Jul;1(1):85-99
references.pmid: 11475537
references.citation: J Neurooncol. 2009 Oct;95(1):61-64
references.pmid: 19381446
references.citation: Cancer Res. 1995 Jun 1;55(11):2325-33
references.pmid: 7757983
references.citation: J Clin Oncol. 2004 May 15;22(10):2015-25
references.pmid: 15143095
references.citation: Prog Drug Res. 2008;66:273, 275-334
references.pmid: 18416309
references.citation: Ann Oncol. 2007 Dec;18 Suppl 12:xii15-20
references.pmid: 18083698
references.citation: Ann Oncol. 2007 Jan;18(1):190-195
references.pmid: 17018704
references.citation: J Clin Oncol. 2007 Mar 20;25(9):1082-8
references.pmid: 17261851
references.citation: J Clin Oncol. 2005 Dec 20;23(36):9120-9
references.pmid: 16301595
references.citation: Cancer Chemother Pharmacol. 2008 Apr;61(5):751-8
references.pmid: 17594093
references.citation: Ann Oncol. 2007 Sep;18(9):1548-53
references.pmid: 17761711
references.citation: Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15798-802
references.pmid: 9861050
references.citation: Cancer Invest. 2005;23(3):264-73
references.pmid: 15948296
references.citation: J Clin Oncol. 2008 May 1;26(13):2223
references.pmid: 18445853
references.citation: Ann Oncol. 2008 May;19(5):977-83
references.pmid: 18296423
references.citation: Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6950-8
references.pmid: 16203787
references.citation: Invest New Drugs. 2006 Nov;24(6):515-20
references.pmid: 16699973
references.citation: Cancer. 2005 May 1;103(9):1932-8
references.pmid: 15800893
references.citation: FEBS J. 2006 Jul;273(14):3301-10
references.pmid: 16803461
references.citation: Breast Cancer Res Treat. 2010 Feb;119(3):663-71
references.pmid: 20012354
references.citation: Acc Chem Res. 2008 Jan;41(1):21-31
references.pmid: 18159935
references.citation: Invest New Drugs. 2006 Sep;24(5):441-6
references.pmid: 16586011
references.citation: Anticancer Res. 2008 Mar-Apr;28(2B):1161-7
references.pmid: 18505052
references.citation: Support Care Cancer. 2003 Mar;11(3):144-7
references.pmid: 12618923
references.citation: Invest New Drugs. 2007 Oct;25(5):487-90
references.pmid: 17520176
references.citation: Cancer Biol Ther. 2007 Apr;6(4):490-3
references.pmid: 17457044
references.citation: Invest New Drugs. 2007 Aug;25(4):327-34
references.pmid: 17347871
references.citation: J Clin Oncol. 2007 Nov 20;25(33):5210-7
references.pmid: 17968020
references.citation: Mol Pharmacol. 2008 Oct;74(4):1072-83
references.pmid: 18593821
references.citation: Clin Cancer Res. 2001 May;7(5):1429-37
references.pmid: 11350914
references.citation: J Clin Oncol. 2007 Aug 10;25(23):3399-406
references.pmid: 17606975
references.citation: Prog Med Chem. 2004;42:171-205
references.pmid: 15003721
references.citation: Nature. 1997 May 15;387(6630):268-72
references.pmid: 9153390
references.citation: Cell Cycle. 2008 Feb 15;7(4):477-83
references.pmid: 18235240
references.citation: Clin Cancer Res. 2008 Jul 15;14(14):4378-84
references.pmid: 18628451
references.citation: Oncologist. 2007 Mar;12(3):271-80
references.pmid: 17405891